

Freedom of Information Request	FOI 22-069	27th January 2022
--------------------------------	------------	-------------------

**I would like to request the following information with regards to primary rebates schemes that have been signed by your CCG/ Board in the past 12 months.**

**1. Are there any signed for any of the following products, and if so , which ones:**

**Insulins (basal, bolus and premix)**

**GLP-1 (i.e Trulicity)**

**DPP-IV (i.e Januvia or Onglyza)**

**SGLT-2 (I.e Invokana)**

**Growth Hormones (norditropin; omnitrope; Genotropin; humatrope; nutropinAq; Saizen)**

Apidra – April 2021 to March 2022

Insuman – April 2021 to Mar 2022

Toujeo - April 2021 to March 2022

Trulicity, Januvia, Onglyza, Invokana – None.

Norditropin, Omnitrope, Genotropin, Humatrope, NutropinAq, Saizen – None.

**2. What are the start and finish dates (or ongoing if open ended)?**

Please see answer to question 1, above

**3. Which rebates are independent? or are they aligned to PrescQIPP?**

We do not use the PrescQIPP rebate platform.

**4. What is the total number of primary rebate schemes (any included) that your CCG/ Board has signed?**

There are 53 active rebates